These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 2478331

  • 1. Correlation of prostate-specific antigen and technetium-99m HMDP bone imaging.
    Shih WJ, Wierzbinski B, Collins J, Pearson TC, Magoun S, Ryo UY.
    Clin Nucl Med; 1989 Oct; 14(10):750-5. PubMed ID: 2478331
    [Abstract] [Full Text] [Related]

  • 2. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
    Shih WJ, Wierzbinski B, Collins J, Magoun S, Chen IW, Ryo UY.
    J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
    [Abstract] [Full Text] [Related]

  • 3. Study of the Usefulness of Bone Scan Index Calculated From 99m-Technetium- Hydroxymethylene Diphosphonate (99mTc-HMDP) Bone Scintigraphy for Bone Metastases from Prostate Cancer Using Deep Learning Algorithms.
    Higashiyama S, Yoshida A, Kawabe J.
    Curr Med Imaging; 2021 Sep; 17(1):89-96. PubMed ID: 32484112
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
    Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE.
    J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma.
    Amico S, Liehn JC, Desoize B, Larbre H, Deltour G, Valeyre J.
    Clin Nucl Med; 1991 Sep; 16(9):643-8. PubMed ID: 1718651
    [Abstract] [Full Text] [Related]

  • 8. Is bone scintigraphy necessary in initial staging of prostate cancer patients?
    Jaukovic L, Adjinovic B, Cerovic S, Joksimovic M, Soldatovic Z.
    Hell J Nucl Med; 2011 Sep; 14(2):126-30. PubMed ID: 21761013
    [Abstract] [Full Text] [Related]

  • 9. The relationship between the serum prostate specific antigen and whole body scintigraphy in prostate cancer patients after prostatectomy.
    Begic A, Kucukalic-Selimovic E, Obralic N, Duric O, Lacevic N, Begovic-Hadzimuratovic S, Skopljak A, Dzubur-Aganovic M.
    Med Arh; 2006 Sep; 60(1):54-5. PubMed ID: 16425536
    [Abstract] [Full Text] [Related]

  • 10. Association of prostate-specific antigen levels and patterns of benign and malignant uptake detected. on bone scintigraphy in patients with newly diagnosed prostate carcinoma.
    Jacobson AF.
    Nucl Med Commun; 2000 Jul; 21(7):617-22. PubMed ID: 10994663
    [Abstract] [Full Text] [Related]

  • 11. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer.
    Miller PD, Eardley I, Kirby RS.
    Br J Urol; 1992 Sep; 70(3):295-8. PubMed ID: 1384920
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase.
    Barichello M, Gion M, Bonazza A, Delli Ponti US, Bolgan A, Contemori GP, Barioli P, Capitanio G, Pecori B, Omacini S.
    Eur Urol; 1995 Sep; 27(4):295-300. PubMed ID: 7544735
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Systematic association of PAP and PSA determinations to bone scintigraphy in prostatic cancer.
    Fincker F, Sauvan R, Pasquier J.
    Am J Clin Oncol; 1988 Sep; 11 Suppl 2():S68-70. PubMed ID: 2468277
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer.
    Spencer JA, Chng WJ, Hudson E, Boon AP, Whelan P.
    Br J Radiol; 1998 Nov; 71(851):1130-5. PubMed ID: 10434906
    [Abstract] [Full Text] [Related]

  • 18. Serial radionuclide imaging during treatment of patients with diffuse bone metastases from carcinoma of the prostate.
    Perkins AC, Hardy JG, Wastie ML, Clifford KM.
    Eur J Nucl Med; 1982 Nov; 7(7):322-3. PubMed ID: 6214398
    [No Abstract] [Full Text] [Related]

  • 19. When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? a retrospective study.
    Lin Y, Mao Q, Chen B, Wang L, Liu B, Zheng X, Xie L.
    BMC Urol; 2017 Jun 12; 17(1):41. PubMed ID: 28606069
    [Abstract] [Full Text] [Related]

  • 20. Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer.
    Hetherington JW, Siddall JK, Cooper EH.
    Eur Urol; 1988 Jun 12; 14(1):1-5. PubMed ID: 2449352
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.